PTC Therapeutics posts Q3 net loss

Overview

• Biopharma firm posted Q3 net loss versus profit a year earlier

• Company raised full-year 2026 revenue and product revenue guidance

Outlook

• PTC Therapeutics raises 2026 total revenue outlook to $1.29-$1.32 bln

• Company lifts 2026 product revenue guidance to $960-$990 mln from $850-$950 mln

• PTC maintains 2026 GAAP R&D and SG&A expense guidance at $775-$815 mln

Result Drivers

• SEPHIENCE LAUNCH - Co said Q3 revenue growth was driven by continued momentum and expansion of Sephience

• SEPHIENCE SALES GROWTH - Sephience sales rose 20% sequentially in Q3, contributing to overall revenue increase

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for PTC Therapeutics, Inc. is $98.00, about 55.5% above its October 28 closing price of $63.02

• The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 67 three months ago

Reuters Recommended Reads

• Oct 29 - Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand

• Oct 29 - Phathom Pharmaceuticals Q3 revenue rises 71%

• Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)